Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.zenithhealthcare.com | |
Market Cap | 22.52 Cr. | |
Enterprise Value(EV) | 21.29 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 0.05 | Trailing Twelve Months Ending 2023-09 |
Price-Earning Ratio (PE) | 88.65 | Trailing Twelve Months Ending 2023-09 |
Industry PE | 38.60 | Trailing Twelve Months Ending 2023-09 |
Book Value / Share | 1.41 | Trailing Twelve Months Ending 2023-09 |
Price to Book Value | 2.97 | Calculated using Price: 4.19 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 5.37 Cr. | 53,739,000 Shares |
FaceValue | 1 | |
About Zenith Health Care Ltd. | ||
Zenith Healthcare is engaged in the manufacturing of tablets, capsules, ointments, and liquid injectable among others. |
1 Day |
|
|
1 Week |
|
-1.18% |
1 Month |
|
+2.70% |
3 Month |
|
-0.71% |
6 Month |
|
+3.46% |
1 Year |
|
-20.19% |
2 Year |
|
-39.10% |
5 Year |
|
+130.22% |
10 Year |
|
+635.09% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | -4.06 | -5.45 | -2.78 | 4.95 | 2.38 | 9.27 | 6.64 | 4.44 | 1.08 | |
Return on Capital Employed (%) | -5.82 | -8.24 | -3.04 | 7.38 | 2.95 | 9.68 | 8.56 | 8.85 | 1.74 | |
Return on Assets (%) | -3.73 | -5.00 | -2.55 | 4.37 | 2.03 | 7.60 | 5.28 | 3.11 | 0.75 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 6 | 6 | 5 | 6 | 6 | 6 | 7 | 7 | 7 | 8 | |
Non Curr. Liab. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Curr. Liab. | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 5 | 2 | 2 | |
Minority Int. | |||||||||||
Equity & Liab. | 6 | 6 | 6 | 7 | 7 | 8 | 8 | 12 | 9 | 10 | |
Non Curr. Assets | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |
Curr. Assets | 4 | 4 | 4 | 5 | 5 | 6 | 6 | 10 | 7 | 8 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 6 | 6 | 6 | 7 | 7 | 8 | 8 | 12 | 9 | 10 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09 Rs. Cr. TTM |
Net Sales | 4 | 3 | 5 | 10 | 10 | 12 | 14 | 22 | 13 | 13 | |
Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | |
Total Income | 4 | 4 | 5 | 10 | 10 | 12 | 14 | 23 | 14 | 13 | |
Total Expenditure | -4 | -4 | -5 | -9 | -10 | -11 | -13 | -22 | -13 | -13 | |
PBIDT | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Taxation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Exceptional Items | |||||||||||
PAT | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |
Adjusted EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 0 | 0 | 0 | 0 | 1 | 0 | 2 | -1 | 1 | -1 | |
Cash Fr. Inv. | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | |
Cash Fr. Finan. | 0 | 0 | 0 | ||||||||
Net Change | -1 | 0 | 0 | 0 | 0 | 0 | 1 | -2 | 1 | -1 | |
Cash & Cash Eqvt | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 1 |
Mon, 06 Nov 2023
Submission Of Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2023 Along With Limited Review Report. The Board consider and approved unaudited Standalone Financial Statement for quarter and half year ended 30th September 2023 along with Limited Review Report. |
Mon, 06 Nov 2023
Related Party Transaction. Related Party Transaction for the quarter and half year ended 30th September 2023. |
Mon, 06 Nov 2023
Board Meeting Outcome for Outcome Of Board Meeting With reference to the above subject we hereby submit the following outcome of the Meeting of the Board of Directors held today November 06 2023 at 3:00 p.m. at the Registered Office of the Company and concluded at 4.00 p.m.:1.The Board considered and approved unaudited Standalone Financial Statement for quarter and Six months ended 30th September 2023 along with Limited Review Report. 2.Considered & approved disclosure of Related Party Transaction u/r 23 (9) of SEBI LODR 2015. |
Wed, 06 Dec 2023 |
|
|
|
|
|